Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858450 · ClinicalTrials.gov registry record
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 3,442,996
- Enrollment target
NCT05858450: Completed study, sponsored by Pfizer.
NCT05858450 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 3,442,996 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05858450 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 3,442,996 participants
- Enrollment target
Study Summary
This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
Primary Outcome
Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). To account for imbalance in participant characteristics between the vaccine exposure groups, 2 separate logistic regression models were used. The two models were: Model 1: Same day vs COVID-19 alone, and Model 2: Same day vs Flu (SIV) alone.
Interventions
- BIOLOGICAL Quadrivalent Influenza Vaccine
- BIOLOGICAL Comirnaty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,442,996 participants |
| Start Date | 2023-05-05 |
| Est. Completion | 2023-05-12 |
What the finished NCT05858450 record still lists
NCT05858450 is an observational study that tracks outcomes without assigning an intervention. Its 3,442,996 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Quadrivalent Influenza Vaccine is the first listed.
NCT05858450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05858450 about?
NCT05858450 is a clinical study titled "This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.". This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
What is the current status of trial NCT05858450?
This trial is currently completed. The enrollment target is 3,442,996 participants. The study started on 2023-05-05. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT05858450?
The interventions under investigation include: Quadrivalent Influenza Vaccine (BIOLOGICAL), Comirnaty (BIOLOGICAL).
Who is sponsoring clinical trial NCT05858450?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI